Cysteine cathepsins and stefins in head and neck cancer: an update of clinical studies

e16007 Background: The National Institute for Health Research Cancer Research Network (NCRN) was established in 2001 to benefit patients by improving the coordination, integration and speed of cancer research. Networks were established in England (NCRN), Scotland, Wales and Northern Ireland, supporting recruitment to a national portfolio across the NHS. In a decade recruitment to cancer studies has increased five fold in England to 20% of new incident cases. Head and Neck cancers affect basic functions including breathing and eating; particularly devastating for patients. The NCRI Head and Neck Cancer Clinical Studies Group is one of 23 Groups funded by NCRI members with a UK wide remit to develop a national portfolio of clinical studies. All CSGs include patients and carers as members resulting in active patient involvement in trial design, patient information and strategic direction of the portfolio. Methods: The last decade has seen unprecedented growth in the Head and Neck portfolio, which now includes 43 studies from only three studies in 2003/4. By 2010/11, 95% of UK Cancer Local Research Networks (37 networks) were recruiting to Head and Neck studies from only 2 networks in 2001/2, expanding trial access for patients and developing Head and Neck research expertise in new sites and with new investigators. Results: Numbers of patients participating in Head and Neck studies has grown exponentially. Since 2006/7 UK patient recruitment has risen 15-fold from 126 to 1890, representing almost 25% new incident cases of Head and Neck cancer. Conclusions: Rapid portfolio growth and associated network activity has expanded opportunities for patients with Head and Neck cancer; providing access to new therapeutic agents and treatment modalities, including NIHR CRN-adopted commercial trials and studies in a surgical setting. Participation in studies demonstrating the effectiveness of Intensity Modulated Radiotherapy in reducing xerostomia (including PARSPORT), has supported integration of this technique into cancer service.

Download Full-text

Head and Neck Cancer: Dedicated FDG PET/CT Protocol for Detection—Phantom and Initial Clinical Studies

Radiology ◽

10.1148/radiol.2433060043 ◽

2007 ◽

Vol 244 (1) ◽

pp. 263-272 ◽

Cited By ~ 37

Author(s):

Yuka Yamamoto ◽

Terence Z. Wong ◽

Timothy G. Turkington ◽

Thomas C. Hawk ◽

R. Edward Coleman

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Neck Cancer ◽

Clinical Studies ◽

Fdg Pet ◽

Pet Ct ◽

Ct Protocol ◽

Fdg Pet Ct

Download Full-text

Clinical studies in head and neck cancer chemoprevention

Cancer and Metastasis Reviews ◽

10.1007/bf00049490 ◽

1996 ◽

Vol 15 (1) ◽

pp. 113-118 ◽

Cited By ~ 3

Author(s):

Pablo M. Gonzalez ◽

Steven E. Benner

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Neck Cancer ◽

Clinical Studies ◽

Cancer Chemoprevention

Download Full-text

Clinical Studies Applying Physical Plasma in Head and Neck Cancer - Key Points and Study Design

International Journal of Clinical Research & Trials ◽

10.15344/2456-8007/2016/103 ◽

2016 ◽

Vol 1 (1) ◽

Cited By ~ 2

Author(s):

Philine Metelmann ◽

David Nedrelow ◽

Matthias Schuster ◽

Rico Rutkowski ◽

Christian Seebauer

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Study Design ◽

Neck Cancer ◽

Clinical Studies ◽

Key Points ◽

Physical Plasma

Download Full-text

Proton Therapy in the Treatment of Head and Neck Cancer

International Journal of Head and Neck Surgery ◽

10.5005/jp-journals-10001-1305 ◽

2017 ◽

Vol 8 (2) ◽

pp. 45-48

Author(s):

Evangelia Katsoulakis ◽

Natalya Chernichenko ◽

David Schreiber

Keyword(s):

Radiation Therapy ◽

Head And Neck Cancer ◽

Head And Neck ◽

Neck Cancer ◽

Proton Therapy ◽

Clinical Studies ◽

Intensity Modulated Radiation Therapy ◽

Added Value ◽

Treatment Modalities ◽

Intensity Modulated

ABSTRACT Aim To examine the value of proton therapy in relation to other treatment modalities in head and neck cancer. Review Proton therapy has evolved into more sophisticated and costly intensity-modulated proton therapy and has resulted in even greater dose reduction to normal critical structures at risk as compared with photon therapy. Early clinical studies in head and neck cancers, especially for tumors of the skull base and paranasal sinuses, suggest that proton therapy is excellent in terms of local control and is comparable to intensity-modulated radiation therapy photons but with lower rates of morbidity. Results There are many potential advantages to radiation therapy with protons. While there are many single institution studies examining the added value of protons to photon therapy, the value of proton therapy must be examined in prospective randomized clinical studies and across many subsites of head and neck cancer. Additional evidence is necessary to guide efficient clinical practice, patient selection, and tumors that are most likely to benefit from this treatment modality and justify proton therapy use given its significant cost. How to cite this article Katsoulakis E, Chernichenko N, Schreiber D. Proton Therapy in the Treatment of Head and Neck Cancer. Int J Head Neck Surg 2017;8(2):45-48.

Download Full-text

Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)

Cancer Chemotherapy and Pharmacology ◽

10.1007/s002800000134 ◽

2000 ◽

Vol 46 (2) ◽

pp. 167-171 ◽

Cited By ~ 24

Author(s):

Nicholas Pavlidis ◽

Steinar Aamdal ◽

Ahmad Awada ◽

Hilary Calvert ◽

Pierre Fumoleau ◽

...

Keyword(s):

Head And Neck Cancer ◽

Malignant Melanoma ◽

Head And Neck ◽

Phase Ii ◽

Neck Cancer ◽

Clinical Studies ◽

Phase Ii Study ◽

Advanced Breast ◽

Hodgkin's Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

Use of Pentoxypline and Tocopherol in the treatment of Osteorradionecrosis: a literature review

Brazilian Journal of Case Reports ◽

10.52600/2763-583x.bjcr.2021.1.2.59-77 ◽

2021 ◽

Vol 1 (2) ◽

pp. 59-77

Author(s):

Jonas Nogueira Ferreira Maciel Gusmão ◽

George Matos Ferreira Gomes Júnior ◽

Roberto Dias Rêgo ◽

Eliardo Silveira Santos

Keyword(s):

Head And Neck Cancer ◽

Conservative Treatment ◽

Literature Review ◽

Head And Neck ◽

Neck Cancer ◽

Clinical Studies ◽

Standard Treatment ◽

Review Of The Literature ◽

Peripheral Vasodilator ◽

New Treatments

Osteoradionecrosis (ORN) is a complication of radiotherapy (RT), which affects patients with head and neck cancer. Once established, an ORN does not disappear spontaneously and a standard treatment has not yet been defined. Treatment is often complex and multimodal. With a better understanding of the pathophysiology of ORN, new treatments and possibilities for the most predictable results of this difficult prognosis pathology arise. Under these circumstances, good results have been observed with an association of peripheral vasodilator drugs and antioxidants, such as pentoxifylline and tocopherol. The objective of this work was, through a review of the literature, to describe a pathophysiology of the ORN of the jaws and discuss as new perspectives of a conservative treatment with pentoxifylline and tocopherol. It was observed as an alternative to the drug association as a therapeutic alternative of the ORN, mainly in the early stages, it showed good results; However, it requires more controlled clinical studies to measure and consolidate the benefits that this treatment can provide patients.

Download Full-text

Population-Based Study of Competing Mortality in Head and Neck Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2011.35.7301 ◽

2011 ◽

Vol 29 (26) ◽

pp. 3503-3509 ◽

Cited By ~ 123

Author(s):

Brent S. Rose ◽

Jong-Hyeon Jeong ◽

Sameer K. Nath ◽

Sharon M. Lu ◽

Loren K. Mell

Keyword(s):

Head And Neck Cancer ◽

High Risk ◽

Head And Neck ◽

Neck Cancer ◽

Mortality Risk ◽

Clinical Studies ◽

Individual Treatment ◽

All Cause Mortality ◽

Competing Mortality ◽

The Impact

Purpose Patients with head and neck cancer (HNC) are at high risk of death resulting from noncancer causes and second malignancies (ie, competing mortality). Variation in competing mortality risk complicates individual treatment choices and design and interpretation of clinical studies. Methods Using the Surveillance, Epidemiology, and End Results registry, we identified 34,568 patients with nonmetastatic squamous cell carcinoma of the head and neck diagnosed between 1994 and 2003. We developed a multivariable competing-risk regression model to stratify patients according to competing mortality risk and evaluate the impact of this risk on power loss in clinical studies. Results The 5-year cumulative incidences of all-cause mortality, HNC-specific mortality, and competing mortality were 51.3% (95% CI, 50.8% to 51.9%), 23.8% (95% CI, 23.3% to 24.2%), and 27.6% (95% CI, 26.8% to 28.3%), respectively. Factors associated with increased competing mortality were increasing age, male sex, black race, unmarried status, localized disease, higher socioeconomic status, nonsurgical treatment, and hypopharyngeal, nasopharyngeal, and oral cavity subsites. The 5-year cumulative incidences of competing mortality for patients in low-, medium-, and high-risk score tertiles were 20.0% (95% CI, 18.8% to 21.3%), 27.7% (95% CI, 26.3% to 29.1%), and 33.7% (95% CI, 32.2% to 35.2%), respectively. Compared with patients with low competing mortality risk, relative sample sizes required to show benefit of a treatment regarding all-cause mortality were 12% and 42% higher in the medium- and high-risk groups, respectively. Conclusion Multiple factors affect risk of competing mortality among patients with HNC. Risk stratification would be useful to identify patients most likely to benefit from treatment intensification.

Download Full-text